Fortress builds on Columbia licence

Oct 17, 2017 •

Biopharmaceutical developer Fortress Biotech has set up a new subsidiary to develop a treatment for amyloidosis licensed from Columbia University.

Columbia University today licensed a therapeutic treatment that could tackle the rare organ disease amyloid light chain (AL) amyloidosis to US-based biopharmaceutical developer Fortress Biotech.

The licence for Columbia’s CAEL-101 antibody has been allocated to Caelum Biosciences, a newly created subsidiary of Fortress to commercialise the therapy.

Fortress has appointed Michael Spector, founder of US-based drug developer North Creek Pharmaceuticals, to run Caelum as chief executive.

AL amyloidosis is a potentially fatal disorder in which malformed proteins produced by bone…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

Can University of Kentucky researchers bring new flavours to whisky?

The University of Kentucky has formed an industry-university partnership to advance aspects such as sustainable agriculture in the whiskey distilling industry.

UK universities ready to pick up the pace of commercialisation in 2025

The UK stands to benefit from the work of the past 12 months to push more university research-led innovation into the marketplace.

Databricks cofounder launches $150m spinout fund with UC Berkeley focus

The investment fund will mostly back founders from the US university.

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.